Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and-resistant Bcr-Abl1-expressing cells

Oncogene

Volumn 29, Issue 22, 2010, Pages 3276-3286

  Albero, M P ^a   Vaquer, J M ^a   Andreu, E J ^b   Villanueva, J J ^a   Franch, L ^a   Ivorra, C ^a   Poch, E ^a   Agirre, X ^b   Prosper, F ^b   Perez Roger I ^a  

^a UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Apoptosis; Bcr Abl1; Bortezomib; CML; Imatinib resistance; Rb

Indexed keywords

BCR ABL PROTEIN; BORTEZOMIB; CASPASE; DASATINIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; RETINOBLASTOMA PROTEIN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BORONIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG TARGETING; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL GROWTH; DRUG EFFECTS; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CASPASES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NF-KAPPA B; PHOSPHORYLATION; PIPERAZINES; PYRAZINES; PYRIMIDINES; RETINOBLASTOMA PROTEIN; BENZAMIDES;

EID: 77953232989     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.81     Document Type: Article

References (42)

1. Adams J. (2001). Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28: 613-619.
2. Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, Martinez-Climent JA et al. (2005). BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 65: 3264-3272.
3. Barre B, Perkins ND. (2007). A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J 26: 4841-4855.
4. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M et al. (2006). Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 98: 1142-1157.
5. Chauhan D, Bianchi G, Anderson KC. (2008). Targeting the UPS as therapy in multiple myeloma. BMC Biochem 9(Suppl 1): S1.
6. Chou TC, Talalay P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
7. Crawford LJ, Windrum P, Magill L, Melo JV, McCallum L, McMullin MF et al. (2009). Proteasome proteolytic profile is linked to Bcr-Abl expression. Exp Hematol 37: 357-366.
8. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. (2004). Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and-independent mechanisms. Blood 104: 509-518.
9. Dasmahapatra G, Nguyen TK, Dent P, Grant S. (2006). Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leuk Res 30: 1263-1272.
10. Druker BJ. (2008). Translation of the Philadelphia chromosome into therapy for CML. Blood 112: 4808-4817.
11. Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, Trombi L et al. (2008). PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 32: 103-112.
12. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G et al. (2003). The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88: 853-863.
13. Griswold IJ, Macpartlin M, Bumm T, Goss VL, O'Hare T, Lee KA et al. (2006). Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 26: 6082-6093.
14. Heaney NB, Pellicano F, Zhang B, Crawford L, Chu S, Kazmi SM et al. (2010). Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopu-lating cells. Blood (e-pub ahead of print 12 January 2010; doi:10.1182/blood-2008-06-164582).
15. Heusch M, Lin L, Geleziunas R, Greene WC. (1999). The generation of nfkb2 p52: mechanism and efficiency. Oncogene 18: 6201-6208.
16. Janicke RU, Walker PA, Lin XY, Porter AG. (1996). Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 15: 6969-6978.
17. Joazeiro CA, Anderson KC, Hunter T. (2006). Proteasome inhibitor drugs on the rise. Cancer Res 66: 7840-7842.
18. Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H et al. (2007). Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leu-kemia/lymphoma cell lines. Invest New Drugs 25: 31-40.
19. Khidr L, Chen PL. (2006). RB, the conductor that orchestrates life, death and differentiation. Oncogene 25: 5210-5219.
20. Kossatz U, Dietrich N, Zender L, Buer J, Manns MP, Malek NP. (2004). Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev 18: 2602-2607.
21. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M et al. (2008). Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 6: 1356-1364.
22. Murray AW. (2004). Recycling the cell cycle: cyclins revisited. Cell 116: 221-234.
23. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. (2008). New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 9: 1157-1165.
24. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. (2006). The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107: 257-264.
25. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. (1999). Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J 18: 5310-5320.
26. Poch E, Minambres R, Mocholi E, Ivorra C, Perez-Arago A, Guerri C et al. (2007). RhoE interferes with Rb inactivation and regulates the proliferation and survival of the U87 human glioblastoma cell line. Exp Cell Res 313: 719-731.
27. Pomerantz JL, Baltimore D. (2002). Two pathways to NF-kappaB. Mol Cell 10: 693-695.
28. Ramirez P, DiPersio JF. (2008). Therapy options in imatinib failures. Oncologist 13: 424-434.
29. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, San Jose-Eneriz E et al. (2007). Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica 92: 153-162.
30. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D et al. (2007). Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13: 5942-5951.
31. Sawyers CL. (1993). The role of myc in transformation by BCR-ABL. Leuk Lymphoma 11: 45-46.
32. Shah NP, Sawyers CL. (2003). Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22: 7389-7395.
33. Sherr CJ, Roberts JM. (2004). Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699-2711.
34. Stapnes C, Doskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB et al. (2007). The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 136: 814-828.
35. Strauss SJ, Higginbottom K, Juliger S, Maharaj L, Allen P, Schenkein D et al. (2007). The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 67: 2783-2790.
36. Van PN, Xinh PT, Kano Y, Tokunaga K, Sato Y. (2005). Establishment and characterization of a novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR/ABL transcripts but missing normal ABL gene. Hum Cell 18: 25-33.
37. Vink J, Cloos J, Kaspers GJ. (2006). Proteasome inhibition as novel treatment strategy in leukaemia. Br J Haematol 134: 253-262.
38. Wei AH, Roberts AW. (2008). Bortezomib: putting mantle cell lymphoma on death row. Leuk Lymphoma 49: 657-658.
39. Yan H, Wang YC, Li D, Wang Y, Liu W, Wu YL et al. (2007). Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta. Leukemia 21: 1488-1495.
40. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. (2008) Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 7: 40.
41. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. (2003). The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102: 3765-3774.
42. Zhao X, Qiu W, Kung J, Peng X, Yegappan M, Yen-Lieberman B et al. (2008). Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res 32: 275-285.